- Home
- PCSA vs DGLY Comparison
PCSA vs DGLY Comparison
Compare PCSA & DGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- DGLY
- Stock Information
- Founded
- PCSA 2011
- DGLY 2004
- Country
- PCSA United States
- DGLY United States
- Employees
- PCSA N/A
- DGLY N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- DGLY Radio And Television Broadcasting And Communications Equipment
- Sector
- PCSA Health Care
- DGLY Technology
- Exchange
- PCSA Nasdaq
- DGLY Nasdaq
- Market Cap
- PCSA 3.3M
- DGLY 3.2M
- IPO Year
- PCSA N/A
- DGLY N/A
- Fundamental
- Price
- PCSA $0.18
- DGLY $1.80
- Analyst Decision
- PCSA Strong Buy
- DGLY
- Analyst Count
- PCSA 1
- DGLY 0
- Target Price
- PCSA $1.00
- DGLY N/A
- AVG Volume (30 Days)
- PCSA 2.8M
- DGLY 108.0K
- Earning Date
- PCSA 10-29-2025
- DGLY 08-18-2025
- Dividend Yield
- PCSA N/A
- DGLY N/A
- EPS Growth
- PCSA N/A
- DGLY N/A
- EPS
- PCSA N/A
- DGLY N/A
- Revenue
- PCSA N/A
- DGLY $18,612,519.00
- Revenue This Year
- PCSA N/A
- DGLY N/A
- Revenue Next Year
- PCSA N/A
- DGLY N/A
- P/E Ratio
- PCSA N/A
- DGLY N/A
- Revenue Growth
- PCSA N/A
- DGLY N/A
- 52 Week Low
- PCSA $0.15
- DGLY $1.66
- 52 Week High
- PCSA $1.50
- DGLY $120.00
- Technical
- Relative Strength Index (RSI)
- PCSA 34.36
- DGLY 38.97
- Support Level
- PCSA $0.16
- DGLY $1.67
- Resistance Level
- PCSA $0.23
- DGLY $1.93
- Average True Range (ATR)
- PCSA 0.02
- DGLY 0.11
- MACD
- PCSA -0.00
- DGLY 0.06
- Stochastic Oscillator
- PCSA 26.71
- DGLY 37.84
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About DGLY Digital Ally Inc.
Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.